Fundraising FoxOmnicyte
New York, US · 1 known investors
Find your way into Omnicyte
Sign up to see every warm intro you have to Omnicyte
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Omnicyte team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OmniCyte is a biotechnology company developing vaccines and cancer immunotherapies, including a SARS-CoV-2 vaccine program and immune-response engineering work conducted in collaboration with academic medical centers. Its research focuses on recombinant vaccine development and immuno-oncology approaches.
Founders & leadership
PL
Peter LeonardiFounder and CEO
AP
Angel PellicerFounder and Investigator
Investors · 1
Related companies · 7
Incyte CorporationIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
CelcuityCelcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.
Rarecyte
Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
KinicitiKiniciti is a platform company that operates cell and gene therapy-focused life science businesses, including Cellistic for iPSC-based manufacturing technologies and Ncardia for human iPSC products and drug discovery services. The company serves therapeutic developers and pharmaceutical companies seeking scalable cell therapy manufacturing and drug discovery solutions.
Lixte Biotechnology HoldingsLixte develops cancer therapies, focusing on precision oncology and clinical drug development. The company works on advancing innovative treatments in the oncology field.
Oncotelic TherapeuticsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Companies working in the same space as Omnicyte.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase I | 2021 | $256K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $199.2K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Omnicyte do?
- OmniCyte is a biotechnology company developing vaccines and cancer immunotherapies, including a SARS-CoV-2 vaccine program and immune-response engineering work conducted in collaboration with academic medical centers. Its research focuses on recombinant vaccine development and immuno-oncology approaches.
- Who founded Omnicyte?
- Omnicyte was founded by Peter Leonardi, Angel Pellicer.
- Who are Omnicyte's investors?
- Omnicyte's investors include Connecticut Innovations.
- Where is Omnicyte headquartered?
- Omnicyte is headquartered in New York, US.